Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA-KT
NCT07806136Phase 1Not yet recruiting
- Sponsor
- Virginia Commonwealth University
- Start
- Aug 2026
- Primary completion
- Feb 2029
01
Overview
Phase 1, randomised, open-label trial in kidney transplantation comparing Standard of Care with MMF Elimination (2 arms). Primary endpoints: Feasibility of Mycophenolate Mofetil Elimination at 6 months, Protocol Adherence at 6 months and 2 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT07806136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806136.